|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS10022|
Organ Preservation Market Overview
Organ preservation is the process under which the organ is preserved under controlled environmental conditions and later can be supplied to hospitals or academic institutes for organ transplantation and research purposes. As per the current scenario, liver, pancreas, and kidney can be successfully preserved for up to two days by flushing the organs with the University of Wisconsin (UW) organ preservation solution and storing them at hypothermia (0–5°C). The UW solution is effective because it uses a number of cells impermeant agents (lactobionic acid, raffinose, and hydroxyethyl starch) that prevent the organs from swelling during cold ischemic storage.
The organ preservation market in terms of preservation method is categorized into the perfusion system, gas mediators, and cold temperature. Among these, the cold temperature category is expected to hold the largest share in the market. This is mainly because cold treatment, including cryopreservation, preserves organs at −196°C for further use, whereas few organs are kept at −4°C for a shorter period of time.
Furthermore, gas mediators can be categorized into hydrogen sulphide (H2S), carbon monoxide (CO), and nitrogen oxide (NO). H2S is used as a standard solution for organ preservation and has the ability to mitigate prolonged storage in cold conditions.
The organ preservation market on the basis of perfusion technique is classified into hypothermic perfusion, subnormothermic perfusion, and normothermic perfusion system. Among these techniques, the hypothermic perfusion category is expected to progress with the highest CAGR, during the forecast period, as it has the potential to improve the outcome of marginal livers and allow viability assessment in high-risk grafts as compared to the normothermic machine perfusion (NMP).
The organ preservation market based on organ is categorized into kidney, lungs, liver, heart, and others. Among these, the kidney category is dominating the market. This is attributed to the increasing cases of renal and liver failure.
The organ preservation market in terms of end user is categorized into organ banks and hospitals & clinics. Between these, the organ banks category dominates the market, as these banks are equipped with technologically advanced products that can keep the organ viable and preserved for a longer duration.
Globally, North America is highly advanced in the practice of organ preservation. Thus, it holds the largest share in the global organ preservation market. For instance, by the end of 2016, there were 312 facilities, performing transplants, which successful track record of kidney transplantation in 19,355 patients. However, the fastest growth is expected to be witnessed by the Asia-Pacific (APAC) region, during the forecast period.
Organ Preservation Market Dynamics
Increased risk of kidney and liver failure, and growing number of surgical transplantation or implantation are boosting the demand for cryopreserved organs in the organ preservation market. For instance, according to an article published in the Nephrology News & Issues Portal, the number of organ transplants has increased substantially in the past 15 years. According to the United Network for Organ Sharing (UNOS), there were 6,992 living donor transplants in 2004, which increased to 7,397 in 2019.
A major challenge associated with organ transplantation is graft rejection. This situation arises when the body’s immune systems rejects the foreign organ being transplanted and leads to adverse effects. Another restraining factor is the shortage of organs for storage and transplantation despite the progress in medical, pharmacologic, and surgical techniques, across the globe.
Organ Preservation Market Competitive Landscape
The key market players are actively participating in the acquisitions and product launches/approvals to gain significant roles in the organ preservation market.
For instance, in June 2018, United Therapeutics Corporation and XVIVO Perfusion Inc., a subsidiary of XVIVO Perfusion AB, announced that the use of XVIVO’s ex-vivo lung perfusion (EVLP) technology would be incorporated into the Silver Spring, Maryland, laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation.
Similarly, in April 2019, the United States Food and Drug Administration (USFDA) approved XVIVO Perfusion Inc.’s XVIVO perfusion system (XPS) with STEEN Solution perfusate. The XPS is responsible for housing the organ for preservation, providing an environment close to body temperature, and perfusing the organ with the STEEN Solution.
Some of the major players in the global organ preservation market are Organ Recovery Systems Inc., Xvivo Perfusion AB, Essential Pharmaceuticals LLC, Transmedics Inc., Paragonix Technologies Inc., 21st Century Medicine Inc., Dr. Franz Kohler Chemie GmbH, Preservation Solutions Inc., OrganOx Limited, Bridge to Life Ltd., and Waters Medical Systems LLC.
The major countries taken into consideration for market size analysis include the U.S., Canada, France, Germany, the U.K., Italy, Spain, Russia, the Netherlands, Japan, China, India, Australia, Brazil, Mexico, Argentina, Saudi Arabia, the U.A.E., and South Africa.